Programme : Back to Dr Spencer Campbell

Bicyclic peptide Drug Conjugates (BDCs) targeting MT1-MMP – a new type of anticancer agent


Bicycle therapeutics is developing novel therapeutic agents based on bicyclic peptides (Bicycles), with a particular focus on treating cancer using Bicycle peptides conjugated to potent anticancer toxins (Bicycle-Drug Conjugates, BDCs). These agents offer significant advantages by combining the best attributes of small molecule and antibody-based therapeutics e.g. high affinity and specificity, high extravasation and tissue penetration, relatively low cost of goods, etc. Our most advanced project targets membrane type-1 matrix metalloproteinase (MT1-MMP), a transmembrane protease involved in physiological and tumour-associated remodelling of the extracellular matrix (ECM). This poster will encompass the discovery, in vitro characterisation, optimisation and in vivo Proof of Concept validation of our BDC directed towards MT1-MMP, due to enter the clinic in 2016.
Add to favourites

Hosted By
The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Find us on Facebook Follow us on Twitter

Get the App
Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
iPhone App
Android App
Eventflo Home
copyright ELRIG, eventflo, Labhoo Ltd 2018